International Myeloma Foundation

MYELOMA MINUTE | Up To The Minute News | 01.11.2024

AI 2024: Is a New Wave of Technology Coming?

In this week’s blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie tackles the coming of a new wave of technology this 2024—AI technology. While concerns have been raised about “hallucinations” (or made-up information generated by chatbots), the many uses of AI technology continue to move forward. Dr. Durie highlights the “containment problem” and other insights discussed by Mustafa Suleyman in his book, The Coming Wave: Technology, Power, and the Twenty-first Century’s Greatest Dilemma. Dr. Durie also touches on the importance and need for ethical guardrails, and the establishment of ground rules, as we deal with the complex impact of AI during these unprecedented times. He has no doubt that AI technology will have an enormous and positive impact on the medical field, especially in determining the best course of treatment and approach for myeloma patients. However, as we continue to grapple with the glitches of this new technology, we should remain vigilant and aware of its flaws. Hopefully, these setbacks will soon be corrected and refined. Dr. Durie remains optimistic about the day-to-day benefits of AI to humanity.

  

 

Share on Facebook LinkedIn

Watch the Replay: Top Myeloma Research at ASH 2023 from a Patient Perspective

IMF Chairman of the Board and Chief Scientific Officer Brian G.M. Durie discussed important Top Myeloma Research and Key Takeaways from the 2023 American Society of Hematology (ASH) Conference, along with a panel of patient advocates including Jessie Daw, PhD, and Michael Tuohy. Together, they sifted through the data of 1,000+ myeloma-related abstracts from the ASH conference and presented key points in approachable terms for everyday decision-making. The replay of this webinar and its slides are now available.

  

 

Share on Facebook LinkedIn

Register Early for the March for Myeloma 5K Run/Walk

This isn't just a run; it's a force for change. During March, we're creating a global wave of awareness for myeloma. This Myeloma ACTION Month, march alongside others in the myeloma community and help us make waves of awareness that touch every corner of the globe. Join us in-person in Boca Raton, FL, or race virtually from wherever you are on Friday, March 15, 2024, at 7:00 a.m EST as we make this journey a pivotal part of Myeloma Action Month 2024.

  

 

Share on Facebook LinkedIn

Join the High-Risk Multiple Myeloma Support Group

The next meeting of the High-Risk Multiple Myeloma Support Group will be on Tuesday, January 16, 2024, at 7 p.m. EST. The group will discuss ASH updates pertinent to the high-risk myeloma population. If interested, reach out to Lissa Gray & Becky Bosley at [email protected].

  

 

Share on Facebook LinkedIn

Watch the IMF’s Videos with Key Opinion Leaders from ASH 2023

In this video, Pieter Sonneveld, MD, PhD, discusses the results of the phase III PERSEUS trial for multiple myeloma patients eligible for autologous stem cell transplantation (ASCT). The PERSEUS trial was one of the most talked about during this year’s ASH. Watch it from the button below and see all of the IMF’s coverage of ASH 2023 here.

  

 

Share on Facebook LinkedIn

Around the Web: Myeloma News

To keep you abreast of the most recent myeloma research findings, “The Myeloma Minute” features links to top myeloma content around the web. This retrospective single-center analysis in Blood Cancer Journal sheds light on the “prognostic impact of additional copies of chromosome 1q+ on outcomes of newly-diagnosed multiple myeloma (NDMM) patients undergoing autologous transplantation (autoSCT).”  Published in the Journal of Clinical Oncology, this study examines “Genomic Classification and Individualized Prognosis in Multiple Myeloma.” Finally, this report finds that “National Cancer Institute (NCI) and nonprofit organization (NPO) funding is critical for research and advocacy but may not be equitable across cancers.” Also, view this wrap-up of top myeloma news in medical journals from December 2023. As always, we invite you to visit the IMF Newsroom for the most recent myeloma news.

  

 

Share on Facebook LinkedIn



Clinical Trial Fact Sheets

KTX-1001 (phase I trial – Now Accruing) 

Phase II Relapsed or Refractory Venetoclax Trial (Fully Accrued)

CANOVA Trial (Fully Accrued)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Webinar Replays

Watch the Replay
IMWG Conference Series: Making Sense of Treatment

Watch the Replay
IMF Patient and Family Webinar

Watch the Replay
M-Power Tampa

See also, all of our events.